Dipeptidyl-peptidase IV (DPP4) inhibitors' cholesterol lowering effect: a systematic review

Background/Aims: Dipeptidyl peptidase-IV (DPP-4) inhibitors are relatively new class of anti-diabetic drugs that have therapeutic potential for management of hypercholesterolemia. Of the numerous DPP4-inhibitors in clinical practice no systematic review has been conducted to compare their anti-hypercholesterolemic effect despite growing evidence of their usefulness in the high risk population. Methods: A systematic review of existing literature investigating cholesterol lowering effects of DPP4 inhibitors was conducted. Published data on DDP-4 inhibitors use for more than 6 months in hypercholesterolemic subjects were sought from Medline, PubMed and Google Scholar search of English language literature from 1994 to 2014 using the key words: "DPP-4 inhibitors", "hypercholesterolemia" "dyslipidemia" and "hyperlipidemia". Results: A total of 6 full text published studies conducted worldwide were included in this systematic review comprising a total of 3968 subjects. Anti-hypercholesterolemic effects range between 13.3% reduction in total cholesterol by Sitagliptin and Vildagliptin to no effect by Linagliptin. On the other hand Saxagliptin demonstrated modest anti-hypercholesterolemic effect. Conclusions: These findings reflected potential benefit of using DPP-4 inhibitors in the management of hypercholesterolemia particularly in subjects with diabetes. Further investigations are required to establish specific anti-hypercholesterolemic effects of DPP-4 inhibitors and to elucidate their clinical application in addition to its established anti-diabetic effects.

Annals of the Australasian College of Tropical Medicine Inc

Annals of the Australasian College of Tropical Medicine

15

1448-4706

N/A

3

1